Thomas A. Mccourt Sells 139,064 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CEO Thomas A. Mccourt sold 139,064 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $244,752.64. Following the completion of the transaction, the chief executive officer now directly owns 1,160,634 shares of the company’s stock, valued at approximately $2,042,715.84. The trade was a 10.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Ironwood Pharmaceuticals Price Performance

IRWD stock opened at $2.01 on Friday. The business has a fifty day moving average price of $3.60 and a 200 day moving average price of $4.17. The stock has a market capitalization of $321.66 million, a price-to-earnings ratio of -67.00 and a beta of 0.29. Ironwood Pharmaceuticals, Inc. has a fifty-two week low of $1.59 and a fifty-two week high of $15.70.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on IRWD shares. JMP Securities dropped their target price on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating for the company in a report on Thursday, January 30th. StockNews.com cut Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Finally, Craig Hallum dropped their price target on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, January 22nd. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Ironwood Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $10.67.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in IRWD. KBC Group NV increased its stake in shares of Ironwood Pharmaceuticals by 59.3% in the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 3,198 shares during the period. Journey Strategic Wealth LLC acquired a new stake in shares of Ironwood Pharmaceuticals in the 4th quarter valued at $45,000. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Ironwood Pharmaceuticals in the 4th quarter valued at $47,000. Xponance Inc. acquired a new stake in shares of Ironwood Pharmaceuticals in the 4th quarter valued at $50,000. Finally, Envestnet Asset Management Inc. acquired a new stake in shares of Ironwood Pharmaceuticals in the 4th quarter valued at $50,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.